FDA ap­proves Am­i­cus' Pom­bil­i­ti + Op­fol­da com­bo ther­a­py for Pompe dis­ease

The FDA on Thurs­day ap­proved Am­i­cus Ther­a­peu­tics’ com­bo ther­a­py for a rare in­her­it­ed lyso­so­mal dis­or­der called Pompe dis­ease fol­low­ing sev­er­al reg­u­la­to­ry de­lays.

The drugs are mar­ket­ed as Pom­bil­i­ti (cipaglu­cosi­dase al­fa) and Op­fol­da (miglu­s­tat). Pom­bil­i­ti is a long-term en­zyme re­place­ment ther­a­py and Op­fol­da is an en­zyme sta­bi­liz­er. The ther­a­py is al­ready ap­proved in the EU, and the UK’s Na­tion­al In­sti­tute for Health and Care Ex­cel­lence rec­om­mend­ed it last month as a first-line ther­a­py as well as in lat­er lines of treat­ment af­ter it re­ceived ap­proval there.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER